Thyroid hormone replacement normalizes renal renin and angiotensin receptor expression in thyroidectomized fetal sheep.
Previous studies have suggested that thyroid hormone influences maturation of the renin-angiotensin system (RAS) and cardiovascular function in the late-gestation fetal sheep. To further examine the importance of thyroid hormone in this regard, we used the technique of thyroidectomy (TX) to remove endogenous thyroid hormone from the circulation and then replaced it with physiological amounts of exogenous thyroxine. We hypothesized that the previously observed changes in RAS activity and cardiovascular function associated with TX would be normalized. TX was performed at 120 days of gestational age (dGA), and control fetuses were sham operated. After 3 days of recovery, TX fetuses were continuously intravenously infused with thyroxine until delivery by cesarean section close to term (around 138 dGA). Immediately before necropsy, fetuses were infused with isoproterenol, and the hemodynamic responses were noted. Thyroid hormone replacement normalized not only plasma triiodothyronine (T3) and thyroxine (T4) levels but also the TX-induced decreases in renal renin mRNA and renal renin content. Renal ANG II subtype receptor expression levels were also normalized for both mRNA and protein. Decreased basal heat rate and systolic blood pressure associated with TX returned to normal following replacement; however, changes in mean blood pressure and isoproterenol-induced changes in mean blood pressure were not altered. These findings demonstrate that replacement of thyroid hormone in hypothyroid sheep fetuses can restore renal ANG II receptor and renin expression and secretion to normal.
Chen
Kai
K
Department of Obstetrics and Gynecology, Center for Research in Obstetrics and Gynecoogy, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1066, USA.
Carey
Luke C
LC
Valego
Nancy K
NK
Rose
James C
JC
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002319:Cardiovascular System / Q000196:embryology; D005260:Female; D015870:Gene Expression / Q000187:drug effects; D005865:Gestational Age; D006340:Heart Rate, Fetal / Q000187:drug effects; D007037:Hypothyroidism / Q000188:drug therapy* / Q000503:physiopathology; D007668:Kidney / Q000196:embryology / Q000502:physiology; D011247:Pregnancy; D044140:Receptor, Angiotensin, Type 1 / Q000235:genetics / Q000378:metabolism*; D044139:Receptor, Angiotensin, Type 2 / Q000235:genetics / Q000378:metabolism*; D012083:Renin / Q000097:blood* / Q000235:genetics; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology; D012756:Sheep; D013965:Thyroidectomy; D013974:Thyroxine / Q000097:blood / Q000494:pharmacology*; D014284:Triiodothyronine / Q000097:blood / Q000494:pharmacology*
D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D014284:Triiodothyronine; D012083:Renin; D013974:Thyroxine